Stock PRLD PROLIGHT DIAGNOSTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Prolight Diagnostics AB

Equities

PRLD

SE0003618230

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
0.133 SEK -6.34% Intraday chart for Prolight Diagnostics AB -10.74% -55.81%
05-17 Prolight Diagnostics Gets SEK17 Million Grant to Advance Product Development MT
02-21 Prolight Diagnostics AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 288.5 119.5 255.1 357.9 152.1 54.76
Enterprise Value (EV) 1 283.7 98.55 239.7 306.7 108.2 0.6495
P/E ratio -96.7 x -17.4 x -50.1 x -75.4 x -22.2 x -
Yield - - - - - -
Capitalization / Revenue 1,408 x 296 x 1,568 x 434 x 1,414 x 1.55 x
EV / Revenue 1,384 x 244 x 1,473 x 372 x 1,006 x 0.02 x
EV / EBITDA - - - - - -51,908 x
EV / FCF - -2,971,195 x -8,894,117 x -15,787,565 x -22,874,225 x -18,310 x
FCF Yield - -0% -0% -0% -0% -0.01%
Price to Book 7.92 x 1.48 x 2.53 x 2.34 x 1.04 x 0.27 x
Nbr of stocks (in thousands) 59,372 94,826 126,299 149,104 149,104 282,269
Reference price 2 4.860 1.260 2.020 2.400 1.020 0.1940
Announcement Date 25/04/18 09/04/19 02/04/20 14/04/21 29/04/22 20/04/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.205 0.404 0.1627 0.8246 0.1075 35.27
EBITDA - - - - - -12.51
EBIT 1 -3.124 -5.811 -4.366 -4.181 -6.951 -12.65
Operating Margin -1,524.01% -1,438.55% -2,683% -507.1% -6,464.07% -35.86%
Earnings before Tax (EBT) 1 -2.85 -5.857 -4.132 -4.3 -6.855 -12.28
Net income 1 -2.85 -5.857 -4.132 -4.3 -6.855 -12.28
Net margin -1,390.15% -1,449.89% -2,539.46% -521.55% -6,374.51% -34.8%
EPS 2 -0.0502 -0.0722 -0.0403 -0.0318 -0.0460 -
Free Cash Flow - -33.17 -26.95 -19.43 -4.73 -35.47
FCF margin - -8,210.71% -16,561.26% -2,356.19% -4,398.58% -100.58%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 25/04/18 09/04/19 02/04/20 14/04/21 29/04/22 20/04/23
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 4.87 20.9 15.5 51.1 43.9 54.1
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -33.2 -26.9 -19.4 -4.73 -35.5
ROE (net income / shareholders' equity) -7.96% -9.89% -4.52% -3.39% -4.58% -6.98%
ROA (Net income/ Total Assets) -4.92% -5.89% -2.87% -2.02% -2.86% -4.43%
Assets 1 57.87 99.42 144 212.5 239.4 277.2
Book Value Per Share 2 0.6100 0.8500 0.8000 1.030 0.9800 0.7300
Cash Flow per Share 2 0 0.0100 0.0100 0.3400 0.2900 0.1900
Capex - - - - - 0.79
Capex / Sales - - - - - 2.25%
Announcement Date 25/04/18 09/04/19 02/04/20 14/04/21 29/04/22 20/04/23
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
PROLIGHT DIAGNOSTICS AB Stock Prolight Diagnostics AB
-55.81% 6.21M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-31.90% 9.3B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-6.25% 3.1B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+25.95% 2.87B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-13.96% 2.17B
VERACYTE, INC. Stock Veracyte, Inc.
-16.83% 1.75B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+72.82% 1.5B
CAREDX, INC Stock CareDx, Inc
+29.17% 807M
SEEGENE, INC. Stock Seegene, Inc.
-2.62% 759M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-26.33% 532M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. PRLD Stock
  4. Financials Prolight Diagnostics AB